Brief: AB Science Gets FDA Authorisation For New Trial In Leukemia

AB Science SA

22/11/2021 17:33

Nov 22 (Reuters) - AB SCIENCE SA  ABS.PA :
    * AB SCIENCE RECEIVED FDA AUTHORIZATION TO INITIATE PHASE
1/II
TRIAL OF AB8939 IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA
    * STUDY AB18001 HAS ALSO BEEN APPROVED IN FRANCE AND IN
CANADA
    * AB8939 WAS GRANTED ORPHAN DRUG DESIGNATION FOR AML FROM
U.S.
FOOD AND DRUG ADMINISTRATION (FDA)
    * THE ESTIMATED TARGETED POPULATION OF AB8938 IN AML IS
AROUND
80,000 PEOPLE IN EUROPE AND THE US

Source text for Eikon:  ID:nGNE4DkzpJ 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))